作 者丨尹华禄 编 辑丨陈思颖 刘雪莹 7月2日晚间，新希望也发布公司独董被查公告并表示，彭龙系公司独立董事，目前除担任公 司独立董事、董事会薪酬与考核委员会委员、董事会风险控制委员会委员、董事会提名委员 会委员外，未担任公司其他职务，不参与公司日常经营管理。上述事项不会对公司生产经营 活动产生重大影响。 苑东生物今年4月发布的年报显示，彭龙曾任西南财经大学党委常委、常务副校长等职务，西 南财经大学金融学院教授。现任西南财经大学金融学院博士生导师、东南大学首席教授、经 济管理学院教授、博士生导师，全国金融专业学位研究生教育指导委员会委员、教育部高等 学校专业设置与教学指导委员会主任委员等职位。2023年5月起任苑东生物独立董事。 公开资料显示，彭龙于1964年出生，毕业于中国科学院系统科学研究所应用数学专业，获博 士学位。1999年起享受国务院政府特殊津贴，2014年入选国家百千万人才工程，被授予"国家 有突出贡献中青年专家"称号。 值得一提的是，彭龙此前曾任北京外国语大学校长。 苑东生物、新希望双双公告：独立董事出事！ 7月2日，创新药上市公司苑东生物（688513.SH）发布公告称，公司于昨日（7月1日） ...

Group 1 - The independent director of Yuan Dong Bio (688513.SH), Peng Long, is under investigation for serious violations of discipline and law, as announced on July 2 [1] - Peng Long holds multiple positions within the company, including independent director and chair of the board's strategic committee, but does not participate in daily operations [1] - The company asserts that this investigation will not have a significant impact on its production and operational activities [1] Group 2 - Peng Long has a notable academic background, having served as a professor and doctoral advisor at Southwest University of Finance and Economics and Southeast University [2] - He has held various prestigious positions, including being a member of the National Financial Professional Degree Graduate Education Steering Committee and the Director of the Ministry of Education's Higher Education Professional Setting and Teaching Guidance Committee [2] - Peng Long was born in 1964 and has received several accolades, including the State Council's special allowance and recognition as a national outstanding young and middle-aged expert [2] Group 3 - Prior to his current roles, Peng Long was the president of Beijing Foreign Studies University [3] - Information regarding Peng Long has been removed from the faculty listings of Southwest University of Finance and Economics and Southeast University [3]

证券代码：688513 证券简称：苑东生物 公告编号：2025-045 成都苑东生物制药股份有限公司 彭龙先生系公司独立董事，目前除担任公司第四届董事会独立董事、董事会 战略委员会主任委员（召集人）、董事会提名委员会委员、董事会审计委员会委 员外，未担任公司其他职务，不参与公司日常经营管理。上述事项不会对公司生 产经营活动产生重大影响。 公司将持续关注上述事项的后续情况，严格按照相关规定及时履行信息披露 义务，敬请广大投资者注意投资风险。 关于公司独立董事接受纪律审查和监察调查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日通 过中共山西省纪律检查委员会、山西省监察委员会网站获悉，公司独立董事、教 育部原副厅级干部彭龙涉嫌严重违纪违法，目前正接受中央纪委国家监委驻教育 部纪检监察组纪律审查和临汾市监委监察调查。 成都苑东生物制药股份有限公司董事会 2025 年 7 月 3 日 1 特此公告。 ...

Group 1 - The company announced that independent director Peng Long is under investigation for serious violations of discipline and law by the Central Commission for Discipline Inspection and the Supervisory Commission of Linfen City [1] - Peng Long currently serves as the independent director of the company's fourth board, chairman of the board's strategic committee, member of the board's nomination committee, and member of the board's audit committee [1] - The company stated that this matter will not have a significant impact on its production and operational activities [1] Group 2 - The company will continue to monitor the progress of the event and will strictly adhere to information disclosure obligations as required [1]

其 他 报 告 2025年06月30日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3424 | -0.70 | -0.51 | | 深证成份指数 | 10379 | 0.34 | -1.16 | | 沪深300指数 | 3922 | -0.61 | -0.45 | | 创业板指数 | 2124 | 0.47 | -1.66 | | 上证国债指数 | 226 | 0.03 | 0.21 | | 上证基金指数 | 6931 | -0.03 | -0.11 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 24284 | -0.17 | -1.52 | | 中国香港国企指数 | 8762 | -0.47 | -1.48 | | 中国台湾加权指数 | 22580 | 0.39 | -0.12 | | 道琼斯指数 | 4381 ...

Core Points - The company announced the first vesting results of the 2024 restricted stock incentive plan, with a total of 418,656 shares vested [1][10] - The shares for this vesting were sourced from the company's repurchase of its A-share common stock from the secondary market [9] Summary of Relevant Sections Decision-Making Process and Disclosure - On April 28, 2024, the company's board and supervisory board approved the draft of the 2024 restricted stock incentive plan and related proposals [2][3] - The plan was publicly disclosed on April 29, 2024, on the Shanghai Stock Exchange website [2] Vesting Details - The total number of shares granted was 1,046,640, with 418,656 shares vested, representing 40% of the granted shares [7] - The vesting included 180 individuals, with core technical personnel and other key employees being the main recipients [9] Stock Source and Structure Changes - The vested shares were sourced from the company's repurchased A-share common stock, meaning there was no change in the total share capital of the company [9] - The controlling shareholder's stake remained unchanged before and after the vesting [9] Verification and Registration - The company received a verification report from an accounting firm confirming the subscription funds for the vested shares, totaling approximately RMB 9.54 million [9][10] - The registration of the vested shares was completed on June 26, 2025, as confirmed by the China Securities Depository and Clearing Corporation [10]

证券代码：688513 证券简称：苑东生物 公告编号：2025-044 成都苑东生物制药股份有限公司 第一个归属期归属结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，成都苑东生物制药股份有限公司（以下 简称"公司"）于 2025 年 6 月 27 日收到中国证券登记结算有限责任公司上海分公 司出具的《过户登记确认书》，完成了公司 2024 年限制性股票激励计划（以下简 称"本次激励计划"）首次授予第一个归属期归属的股份登记工作。现将有关情况 公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2024 年 4 月 28 日，公司召开的第三届董事会第十八次会议，审议通 过了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2024 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股 东大会授权董事会办理公司 2024 年限制性股票激励计划有 ...

Group 1 - The core viewpoint of the news is that Yuandong Biopharmaceutical is accelerating its strategic transformation by increasing its stake in Shanghai Chaoyang, which specializes in innovative drug development [1][2] - Yuandong Biopharmaceutical's subsidiary plans to acquire approximately 19.32% of Shanghai Chaoyang's shares, raising its indirect ownership from 11.36% to 30.68%, thus gaining significant influence over the company [1] - The acquisition aligns with Yuandong's strategic development plan and is expected to enhance its capabilities in innovative drug research and development [1][2] Group 2 - Shanghai Chaoyang, established in 2021, focuses on innovative drug research in oncology and autoimmune diseases, utilizing advanced technologies such as protein homeostasis and computer-aided drug design [2] - The company has filed 11 invention patent applications and holds 2 authorized patents, with multiple research pipelines targeting various diseases [2] - Experts believe that the increased stake will allow Yuandong to participate more deeply in Shanghai Chaoyang's R&D processes, enhancing its competitive position in the innovative drug sector [2][3] Group 3 - The innovative drug sector is experiencing rapid growth due to advancements in biotechnology and increasing global demand for effective treatments for major diseases [3] - Governments worldwide are implementing policies to support innovative drug development, providing financial backing to enhance research efforts [3] - The integration of emerging technologies like artificial intelligence and big data is expected to improve the efficiency and success rates of innovative drug development [3]

Group 1 - The smart medical sector is experiencing a significant upward trend, with notable stock price increases for several companies [1] - Jincheng Pharmaceutical (300233) has seen its stock rise by over 10% [1] - Heertai (002402) and Weining Health (300253) have both increased by over 9% [1] - Yaoshi Technology (300725) has experienced a stock price increase of over 5% [1] - Other companies such as Yuandong Biology and Chengdu Xian Dao are also showing upward movement [1]

Core Viewpoint - The report highlights the commitment of Yuan Dong Bio to sustainable development through a robust ESG (Environmental, Social, and Governance) framework, emphasizing innovation, compliance, and social responsibility in the pharmaceutical industry [1][2][3]. Group 1: Company Overview - Yuan Dong Bio is dedicated to patient-centered healthcare, focusing on innovation and quality in drug development, with a significant portion of revenue allocated to R&D, exceeding 20% [2][3]. - The company has established a comprehensive governance structure, including a board of directors and various committees to ensure effective decision-making and compliance with regulations [4][5]. Group 2: ESG Commitment - The company integrates ESG principles into its core strategy, aiming for a harmonious balance between environmental sustainability, social responsibility, and corporate governance [1][5]. - Yuan Dong Bio has implemented a three-tier ESG governance structure, comprising the board, an ESG management committee, and an execution team, to oversee and enhance its sustainability initiatives [5]. Group 3: Innovation and Development - The company has a strong focus on innovation, with over 80 ongoing projects, including 18.3% dedicated to new drug development, and has achieved significant milestones in clinical trials [3][5]. - Yuan Dong Bio has successfully launched multiple high-end pharmaceutical products, including 8 domestic first generic products and 14 active pharmaceutical ingredients that meet international standards [3][4]. Group 4: Social Responsibility - The company actively engages in community support initiatives, including healthcare assistance and educational programs, reflecting its commitment to social responsibility and public health [2][5]. - Yuan Dong Bio emphasizes employee welfare and development, recognizing its workforce as a vital asset, and has implemented various programs to support employee growth and well-being [2][5].